# Catalyst Biosciences To Present at the Ladenburg Thalmann 2016 Healthcare Conference

September 23, 2016

**-- Presentation will Focus on Preclinical Data and Development Strategy for Subcutaneous Prophylaxis of Individuals with Hemophilia --**

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biotechnology company focused on creating and developing novel protease therapeutics to treat serious medical conditions in the field of hemostasis, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held in New York City September 27, 2016.

***Ladenburg Thalmann 2016 Healthcare Conference – Catalyst Biosciences Presentation Details***
Date: Tuesday, September 27, 2016
Time: 3:00 p.m. Eastern Time
Location: Sofitel New York, New York City, St. Germain Room

**About Hemophilia and Factor Replacement Therapy**
Hemophilia, for which there is no cure, is a rare but serious bleeding disorder that results from a genetic or an acquired deficiency of a protein required for normal blood coagulation. There are two major types of hemophilia, A and B, that are caused by alterations in Factor VIII or Factor IX genes, respectively, with a corresponding deficiency in the affected proteins. The prevalence of hemophilia A and B in the United States is estimated to be around 20,000 people, with more than 400,000 cases worldwide. Individuals with hemophilia suffer from spontaneous bleeding episodes as well as substantially prolonged bleeding times upon injury. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in permanent, disabling joint damage and can become life threatening. Treatment usually involves management of acute bleeding episodes or prophylaxis with factor replacement therapy by intravenous (IV) infusion of an individual's missing Factor VIII or IX or, in the case of individuals who have developed inhibitors to their replacement factor, FVIIa. Adherence to a prophylaxis regimen is difficult because of the frequent IV infusion schedule of most currently approved therapies. In addition, convenient access to peripheral veins is often a problem, and many children require insertion of a central venous access device, with the concomitant risks of infection and thrombosis.

**About Marzeptacog alfa (activated) Factor VIIa**
Marzeptacog alfa (formerly known as CB 813d) is a highly potent next-generation Factor VIIa that has successfully completed an IV Phase 1 clinical trial in individuals with severe hemophilia A and B both with and without inhibitors. Marzeptacog alfa (activated) was designed to combine higher clot-generating activity (high potency) at the site of bleeding and is being developed for the subcutaneous prophylaxis of individuals with severe hemophilia A and B with inhibitors.

**About Factor IX**
CB 2679d/ISU304 is a next-generation high potency coagulation Factor IX variant that is in advanced preclinical development. CB 2679d has exhibited enhanced procoagulant activity, improved efficacy in reducing blood loss, and prolonged duration of action in bleeding and non-bleeding preclinical models compared with other Factor IX products on the market and in development. Based on these findings, Catalyst believes that CB 2679d may allow for subcutaneous dosing in individuals with hemophilia B. Catalyst is developing CB 2679d in collaboration with ISU Abxis (KOSDAQ:086890) through a Phase 1/2 proof-of-concept subcutaneous administration study in individuals with hemophilia B. Following completion of the Phase 1/2 study, ISU Abxis has an option for exclusive commercial rights in South Korea while Catalyst retains full development and commercial rights for CB 2679d outside of South Korea.

**About Catalyst**
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. Catalyst's most advanced program is an improved next-generation coagulation Factor VIIa variant, marzeptacog alfa (activated), that has successfully completed an intravenous Phase 1 clinical trial in individuals with severe hemophilia A and B. Catalyst is also developing a next-generation Factor IX variant, CB 2679d/ISU304, that is in advanced preclinical development. For more information, please visit www.catalystbiosciences.com.

**Forward-Looking Statements**
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this press release regarding the Company's product candidates, including product development plans for CB 2679d and marzeptacog alfa (activated), plans for and timing of clinical trials, and the potential uses of the Company's product candidates are forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, potential adverse effects arising from the testing or use of the Company's products, the risk that costs required to develop or manufacture the Company's products will be higher than anticipated, risks related to the Company's ability to protect or enforce intellectual property rights related to its product candidates, competition and other factors that affect the Company's ability to establish collaborations on commercially reasonable terms and the Company's ability to successfully develop and commercialize its product candidates. Other risks and uncertainties related to the Company's business are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Investors:
Andrew McDonald

Managing Director
LifeSci Advisors, LLC
+1.646.597.6987
andrew@lifesciadvisors.com

Fletcher Payne, CFO
Catalyst Biosciences, Inc.
+1.650.871.0761
investors@catbio.com

Media:
Denise Powell
Red House Consulting, LLC
+1.510.703.9491
denise@redhousecomms.com


Catalyst Biosciences, Inc.